Date: 2013-06-11
Type of information:
phase: 2
Announcement:
Company: Genmab (Denmark) River Vision Development Corporation (USA)
Product: teprotumumab (RG1507)
Action mechanism: Teprotumumab is a fully human antibody that targets the Insulin-like Growth Factor-1 Receptor (IGF-1R).
Disease: active thyroid eye disease
Therapeutic area: Ophtalmological diseases
Country:
Trial details: The purpose of this study is to evaluate the safety, tolerability and effectiveness of a fully human antibody compared to placebo in the treatment of patients with active thyroid eye disease. (NCT01868997)
Latest
news: * On June 11, 2013, Genmab has announced that teprotumumab (RG1507), an antibody developed by Genmab under our collaboration with Roche, will restart clinical development in a Phase 2 study in patients with active thyroid eye disease. Clinical development will be conducted by River Vision Development Corporation, who licensed teprotumumab from Roche.
Under River Vision Development's collaboration with Roche, Genmab will receive milestones as well as royalty payments on successful products.
